Back To TOP

Co-pay Cards Genentech BioOncology™ Co-pay Card

The Genentech BioOncology Co-pay Card may be able to help with the out-of-pocket costs of your PERJETA® (pertuzumab) prescription.

activate card

 


 

Qualified Patients*

  • I am covered by commercial insurance

    - To answer "yes" to this question, you cannot be covered by a government-funded health care program such as Medicare, Medicaid, Medigap, VA, DoD or Tricare

  • I am age 18 years or older
  • I currently live or get treatment in the United States or Puerto Rico

 

If you answered "yes" to all the questions above, you are eligible.

 

* If you are receiving funding from the Genentech® Access to Care Foundation, you are not eligible for the Genentech BioOncology Co‐pay Card.
Vermont state laws do not allow programs like this.

 


 

What the card covers

 

 

Need help with enrollment? Call (855) MYCOPAY/(855) 692-6729.

Learn More About
PERJETA
  • LEARN about treatment with PERJETA
  • LEARN HOW the Genentech BioOncology Co-pay Card can help with the out-of-pocket costs for PERJETA
  • Form Patient Authorization and Notice of Release of Information

What does PERJETA treat?

PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel (chemotherapy) in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

PERJETA® (pertuzumab) is approved for use prior to surgery in combination with Herceptin® (trastuzumab) and docetaxel (chemotherapy) in people with HER2-positive, locally advanced, inflammatory, or early stage (tumor is greater than 2 cm in diameter or node positive) breast cancer. PERJETA should be used as part of a complete treatment regimen for early stage breast cancer. This use of PERJETA is based on an improvement in the percentage of patients whose cancer shrinks or disappears after treatment. Currently, no data have shown whether or not treatment with PERJETA prior to surgery improves survival.

  • The safety of PERJETA in combination with doxorubicin-containing regimens has not been established
  • The safety of PERJETA administered following surgery has not been established

Important Safety Information

    • PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure)
    • Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects

- If you think you may be pregnant, you should contact your healthcare provider immediately

- If you are exposed to PERJETA during pregnancy, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting
  1-800-690-6720

    • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA
    • Other possible serious side effects of PERJETA therapy include:

- Infusion-related reactions

- Severe allergic reactions (hypersensitivity reactions/anaphylaxis)

  • PERJETA has only been shown to work in people with HER2-positive breast cancer
  • The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) for treatment of breast cancer that has spread to other parts of the body (metastatic) are:

- Diarrhea

- Hair loss

- Low levels of white blood cells with or without a fever

- Nausea

- Feeling tired

- Rash

- Damage to the nerves (numbness, tingling, pain in hands/feet)

  • The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) as part of an early breast cancer regimen before surgery are:

- Hair loss

- Diarrhea

- Nausea

- Low levels of white blood cells with or without a fever

  • The most common side effects of PERJETA when given with Herceptin and docetaxel following 3 cycles of epirubicin, cyclophosphamide, and fluorouracil as part of an early breast cancer regimen before surgery are:

- Feeling tired

- Hair loss

- Diarrhea

- Nausea

- Vomiting

- Low levels of white blood cells with or without a fever

  • The most common side effects of PERJETA when given with Herceptin, docetaxel, and carboplatin as part of an early breast cancer regimen before surgery are:

- Feeling tired

- Hair loss

- Diarrhea

- Nausea

- Vomiting

- Low levels of white blood cells with or without a fever

- Low platelet count

- Low levels of red blood cells

 

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see PERJETA full Prescribing Information, including Most Serious Side Effects, for additional Important Safety Information.

PERJETA® and the Access Solutions logo are registered trademarks of Genentech, Inc.